Ozempic Impact on Comorbidities is Limited GLP-1 shots do not address many obesity-related health issues as effectively as a more permanent solution like bariatric surgery
Back Edwards, K, Li, X, Linvay, I (1 April 2023) 'Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A real-world study', The Journal of Clinical Endocrinology & Metabolism , 108/ 4, 92030
adults had already taken GLP-1 at some point and the global market is projected to triple in the next five years, driven by high and rising levels of type-2 diabetes and obesity, aging populations, urbanization and public health initiatives: (2018-2030E) Global pharmaceutical companies dominate todays production: With ~300 clinical trials around the world, research continues into applications to other metabolic disorders, cardiovascular and kidney disease and neurological conditions
1,3 Metabolic health: Supports cardiovascular and energy balance by influencing lipid metabolism and body weight
A 2021 report published by the National Library of Medicine revealed that adult obesity is associated with average annual increased medical costs per person of $1,861
Viking Therapeutics continues to appear in investor conversations as a recurring acquisition target because VK2735 offers both injectable and oral potential
)
